KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Assets (2016 - 2025)

Historic Assets for Pacira BioSciences (PCRX) over the last 17 years, with Q3 2025 value amounting to $1.3 billion.

  • Pacira BioSciences' Assets fell 1472.8% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year decrease of 1472.8%. This contributed to the annual value of $1.6 billion for FY2024, which is 132.56% down from last year.
  • According to the latest figures from Q3 2025, Pacira BioSciences' Assets is $1.3 billion, which was down 1472.8% from $1.5 billion recorded in Q2 2025.
  • In the past 5 years, Pacira BioSciences' Assets ranged from a high of $2.1 billion in Q4 2021 and a low of $1.3 billion during Q1 2021
  • Moreover, its 5-year median value for Assets was $1.6 billion (2024), whereas its average is $1.6 billion.
  • As far as peak fluctuations go, Pacira BioSciences' Assets skyrocketed by 6283.5% in 2021, and later crashed by 1945.88% in 2023.
  • Over the past 5 years, Pacira BioSciences' Assets (Quarter) stood at $2.1 billion in 2021, then decreased by 18.99% to $1.7 billion in 2022, then decreased by 6.35% to $1.6 billion in 2023, then dropped by 1.33% to $1.6 billion in 2024, then dropped by 16.47% to $1.3 billion in 2025.
  • Its Assets was $1.3 billion in Q3 2025, compared to $1.5 billion in Q2 2025 and $1.6 billion in Q1 2025.